Palisade bio announces reverse stock split

Carlsbad, ca, nov. 15, 2022 (globe newswire) -- palisade bio , inc.  (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, today announced a 1-for-50 reverse split of its common stock, par value $0.01 (“common stock”), effective at 4:01 pm et today. beginning on november 16, 2022, the company's common stock will continue to trade on the nasdaq capital market (“nasdaq”) on a split adjusted basis under the trading symbol “pali,” but will trade under the following new cusip number starting november 16, 2022: 696389204.
PALI Ratings Summary
PALI Quant Ranking